Ohno, Shigeaki http://orcid.org/0000-0001-6964-6094
Umebayashi, Itsuro
Matsukawa, Miyuki
Goto, Takashi
Yano, Toshiro
Article History
Received: 31 July 2018
Accepted: 11 December 2018
First Online: 5 January 2019
Ethics approval and consent to participate
: This PMS study protocol was approved by the Ministry of Health, Labor and Welfare of the Japan Government, and was conducted in accordance with good post-marketing surveillance practice (GPSP), which sets the standard for PMS studies of approved drugs in clinical practice. Patients were treated in accordance with physicians’ usual clinical practice and indication for commercially available IFX.; no consent was needed by the institutions’ ethics committees.
: Not applicable.
: SO has received expert testimony fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Alcon Japan, Bosch & Lomb Japan, and Santen Pharmaceutical Company; grants/research support from Mitsubishi Tanabe Pharma Corporation; lecture fees from Mitsubishi Tanabe Pharma Corporation, Alcon Japan, Otsuka Pharmaceutical Company, and Santen Pharmaceutical Company; patent fees from Mitsubishi Tanabe Pharma Corporation. IU, MM, TG, and TY are full-time employees of Mitsubishi Tanabe Pharma Corporation.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.